Navigation Links
Skin flaps deliver cancer-fighting therapy, ASPS study reveals
Date:5/8/2008

ARLINGTON HEIGHTS, Ill. Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS). This new delivery technique, which has yet to be tested in humans, did not cause toxicity in the body of rats; however, administering the same anti-tumor agent intravenously in humans has previously been shown to cause liver damage.

This new technique may allow us to reprogram skin flaps, using gene therapy, to provide a blueprint for anti-tumor agents like Interleukin-12 to be produced in the tumor to kill cancer, while avoiding adverse side effects, said Geoffrey Gurtner, MD, ASPS Member and study senior author. In this study we took skin flaps in animal models and delivered IL-12 directly to the tumor area with tremendous success. Since skin flaps are used thousands of times each year in cancer patients, this may potentially open up an entirely new area in plastic surgery and bring the specialty, once again, to the center of medicine.

Gene therapy has been heralded as a new tool to restrain or prevent tumor growth and recurrence in humans, but its use has been limited because of serious side effects and the difficulty in concentrating anti-tumor agents at the site of the cancer.

In the study, skin flaps (a mass of healthy tissue) taken from rats were injected with the gene for IL-12 into the flaps blood supply. The flaps were then placed onto cancerous tumors on the rats.

The study found a 79 percent reduction in tumor volume for animals treated with IL-12 compared to control animals. The treatment allowed individual cells within the flap to become encoded with IL-12 and function as miniature factories producing the IL-12 protein at very high levels in the tumor site, according to the study.

Additionally, the serious side effects previously documented with systemic use of IL-12 were not found in the treated rats. The liver, lung and spleen remained normal throughout the study. The delivery technique through free flaps did not cause liver toxicity, whereas using IL-12 intravenously in humans has been shown to cause liver damage.

This could be a major advance for the delivery of a therapeutic agent to diseased parts of the body, said Dr. Gurtner. I can see this therapy being used for breast cancer, head and neck cancers, central nervous system malignancies, and somewhere down the line hemophilia, diabetes and infections.

The study authors concluded that as oncologic reconstructive surgery is a major component of plastic surgery, the delivery of a healing agent precisely to the region where cancer was and where local recurrences are most likely to occur, could add a new dimension to the reconstructive function of free flaps in oncologic and reconstructive plastic surgery.


'/>"/>

Contact: ASPS Media Relations
media@plasticsurgery.org
847-228-9900
American Society of Plastic Surgeons
Source:Eurekalert

Related medicine news :

1. Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008
2. KePROs Chief Medical Officer to Deliver Clinical Keynote Address
3. Doctors Discover Marker for Meconium Passage During Delivery
4. Integrium Introduces Its Integrium Clinical Excellence (ICE) Methodology to Assure Consistent Delivery of Sponsor Clinical Trials
5. Mothers with Breast Cancer Can Dine to Thrive with Gourmet Meal Delivery
6. Medco Joins Cincinnatis Cover the Uninsured Week Effort To Deliver Lower Cost Health Care
7. SpongeTech(R) Delivery Systems, Inc. Clarification of Yesterdays $7,500,000 Order of Uncle Normans(TM) Pet Sponge
8. LMS CALM(R) receives high customer satisfaction scores in the 2008 KLAS Labor and Delivery report
9. The Heritage Group Selects AccuNurse(R) to Improve Efficiency and Deliver Proactive Care
10. The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference
11. Echo Therapeutics and Cato BioVentures Sign Right of First Offer Agreement for Dermatology Products and Transdermal Drug Delivery Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room ... Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with ... Latin America . ... ... ... ...
Breaking Medicine Technology: